Corcept Therapeutics (CORT) Tops Q1 EPS by 3c, increases guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $111.62 --0%
EPS Growth %: +393.8%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +393.8%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of $0.25, $0.03 better than the analyst estimate of $0.22. Revenue for the quarter came in at $146.81 million versus the consensus estimate of $141.19 million.
GUIDANCE:
Corcept Therapeutics sees FY2024 revenue of $620-650 million, versus the consensus of $610.6 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
- Prabhudas Lilladher Upgrades GE Vernova T&D India (GVTD:IN) to Buy (1)
- Morgan Stanley Downgrades Infineon Technologies (IFX:GY) (IFNNY) to Equalweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
